Abstract
The prevalence of flying Hymenoptera venom hypersensitivity in patients with mast cell activation disorders (MCADs) is approximately 25% vs 2% in the general population. 1 Niedoszytko M. Bonadonna P. Oude-Elberink J.N.G. Golden D.B.K. Epidemiology, diagnosis, and treatment of Hymenoptera venom in allergy in mastocytosis patients. Immunol Allergy Clin North Am. 2014; 34: 365-381 Abstract Full Text Full Text PDF PubMed Scopus (41) Google Scholar Previous studies have reported success with venom immunotherapy (VIT) for flying Hymenoptera hypersensitivity in the setting of MCADa. 2 Gonzalez de Olano D. Alvarez-Twose I. Esteban-Lopez M. et al. Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis. J Allergy Clin Immunol. 2008; 121: 519-526 Abstract Full Text Full Text PDF PubMed Scopus (109) Google Scholar To date, there are no cases of hypersensitivity to the imported fire ant (IFA), Solenopsis invicta/Solenopsis richteri specifically, in patients with MCADa in the literature. Moreover, this case series is the first, to our knowledge, to describe patients with MCADs and documented IFA hypersensitivity who have successfully completed the build-up phase of IFA–whole body extract (WBE) immunotherapy using conventional and rush protocols.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
